Portal del Investigador
A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis
Más información
| Fecha de publicación: | 2017 |
| Objetivos: | Time From Randomization to Relapse in the Double-blind (DB) Period [ Time Frame: From randomization in the DB period through 26 weeks ] |
| Año de Inicio/Término: | 2017-2019 |
| Financiamiento/Sponsor: | ACADIA Pharmaceuticals Inc. |
| Rol del Usuario: | COINVESTIGADOR(A) |
| URL: | NCT03325556 |
| DOI: |
ACP-103-045 |